[go: up one dir, main page]

WO2002043806A3 - In vivo delivery methods and compositions - Google Patents

In vivo delivery methods and compositions Download PDF

Info

Publication number
WO2002043806A3
WO2002043806A3 PCT/US2001/044352 US0144352W WO0243806A3 WO 2002043806 A3 WO2002043806 A3 WO 2002043806A3 US 0144352 W US0144352 W US 0144352W WO 0243806 A3 WO0243806 A3 WO 0243806A3
Authority
WO
WIPO (PCT)
Prior art keywords
blood
detecting
viscosity
living
heart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/044352
Other languages
French (fr)
Other versions
WO2002043806A2 (en
Inventor
Kenneth Kensey
Charles Hokanson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rheologics Inc
Original Assignee
Rheologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/819,924 external-priority patent/US20010044584A1/en
Application filed by Rheologics Inc filed Critical Rheologics Inc
Priority to AU2002226986A priority Critical patent/AU2002226986A1/en
Publication of WO2002043806A2 publication Critical patent/WO2002043806A2/en
Publication of WO2002043806A3 publication Critical patent/WO2002043806A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/02028—Determining haemodynamic parameters not otherwise provided for, e.g. cardiac contractility or left ventricular ejection fraction
    • A61B5/02035—Determining blood viscosity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/02028—Determining haemodynamic parameters not otherwise provided for, e.g. cardiac contractility or left ventricular ejection fraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3607—Regulation parameters
    • A61M1/3609—Physical characteristics of the blood, e.g. haematocrit, urea
    • A61M1/361—Physical characteristics of the blood, e.g. haematocrit, urea before treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3672—Means preventing coagulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/026—Measuring blood flow
    • A61B5/029—Measuring blood output from the heart, e.g. minute volume
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/04—Heartbeat characteristics, e.g. ECG, blood pressure modulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Anesthesiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.
PCT/US2001/044352 2000-12-01 2001-11-27 In vivo delivery methods and compositions Ceased WO2002043806A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002226986A AU2002226986A1 (en) 2000-12-01 2001-11-27 In vivo delivery methods and compositions

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US72795000A 2000-12-01 2000-12-01
US09/727,950 2000-12-01
US09/819,924 2001-03-28
US09/819,924 US20010044584A1 (en) 1997-08-28 2001-03-28 In vivo delivery methods and compositions
US09/828,761 US20020061835A1 (en) 1997-08-28 2001-04-09 In vivo delivery methods and compositions
US09/828,761 2001-04-09
US09/839,785 2001-04-20
US09/839,785 US20030078517A1 (en) 1997-08-28 2001-04-20 In vivo delivery methods and compositions

Publications (2)

Publication Number Publication Date
WO2002043806A2 WO2002043806A2 (en) 2002-06-06
WO2002043806A3 true WO2002043806A3 (en) 2003-03-27

Family

ID=27505576

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/044352 Ceased WO2002043806A2 (en) 2000-12-01 2001-11-27 In vivo delivery methods and compositions

Country Status (2)

Country Link
AU (1) AU2002226986A1 (en)
WO (1) WO2002043806A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348362B2 (en) 2003-07-10 2008-03-25 Dey, L.P. Bronchodilating β-agonist compositions and methods

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US10028858B2 (en) 2011-07-11 2018-07-24 Medicines360 Intrauterine systems, IUD insertion devices, and related methods and kits therefor
USD718435S1 (en) 2012-05-30 2014-11-25 Medicines360 Intrauterine insertion device
CN107789693B (en) * 2017-10-31 2019-07-23 四川南格尔生物科技有限公司 A kind of sampled plasma system optimizing anti-coagulants dosage

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041430A (en) * 1989-09-18 1991-08-20 Du Pont Mereck Pharmaceutical Company Oral anticoagulant/platelet inhibitor low dose formulation
WO1999010724A2 (en) * 1997-08-28 1999-03-04 Visco Technologies, Inc. Viscosity measuring apparatus and method of use
WO2001058356A2 (en) * 2000-02-10 2001-08-16 Rheologics, Inc. Method for determining absolute and effective blood viscosity
WO2002009583A2 (en) * 2000-08-01 2002-02-07 Rheologics, Inc. Apparatus and methods for comprehensive blood analysis, including work of, and contractility of, heart and therapeutic applications and compositions thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041430A (en) * 1989-09-18 1991-08-20 Du Pont Mereck Pharmaceutical Company Oral anticoagulant/platelet inhibitor low dose formulation
WO1999010724A2 (en) * 1997-08-28 1999-03-04 Visco Technologies, Inc. Viscosity measuring apparatus and method of use
WO1999066839A1 (en) * 1997-08-28 1999-12-29 Visco Technologies, Inc. In-vivo determining the effects of a pharmaceutical on blood parameters
WO2001058356A2 (en) * 2000-02-10 2001-08-16 Rheologics, Inc. Method for determining absolute and effective blood viscosity
WO2002009583A2 (en) * 2000-08-01 2002-02-07 Rheologics, Inc. Apparatus and methods for comprehensive blood analysis, including work of, and contractility of, heart and therapeutic applications and compositions thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARMSTRONG J K ET AL: "COVALENT BINDING OF POLY(ETHYLENE GLYCOL) (PEG) TO THE SURFACE OF RED BLOOD CELLS INHIBITS AGGREGATION AND REDUCES LOW SHEAR BLOOD VISCOSITY", AMERICAN JOURNAL OF HEMATOLOGY, NEW YORK, NY, US, vol. 56, no. 1, September 1997 (1997-09-01), pages 26 - 28, XP000827783 *
MEDICAL RESEARCH COUNCIL'S GENERAL PRACTICE RESEARCH FRAMEWORK T: "Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk", LANCET, XX, XX, vol. 351, no. 9098, 24 January 1998 (1998-01-24), pages 233 - 241, XP004265259, ISSN: 0140-6736 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348362B2 (en) 2003-07-10 2008-03-25 Dey, L.P. Bronchodilating β-agonist compositions and methods
US7462645B2 (en) 2003-07-10 2008-12-09 Jpmorgan Chase Bank, N.A. Bronchodilating beta-agonist compositions and methods
US7465756B2 (en) 2003-07-10 2008-12-16 Jpmorgan Chase Bank, N.A. Bronchodilating beta-agonist compositions and methods
US7473710B2 (en) 2003-07-10 2009-01-06 Jpmorgan Chase Bank, N.A. Bronchodilating beta-agonist compositions and methods
US7541385B2 (en) 2003-07-10 2009-06-02 Chaudry Imtiaz A Bronchodilating β-agonist compositions and methods

Also Published As

Publication number Publication date
AU2002226986A1 (en) 2002-06-11
WO2002043806A2 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
Sowers Hypertension, angiotensin II, and oxidative stress
WO2006023803A3 (en) Methods of administering microparticles combined with autologous body components
BRPI0414455A (en) Methods for Using Regenerative Cells to Treat Peripheral Vascular Disease and Related Disorders
WO2002079778A3 (en) In vivo delivery methods and compositions
WO2000018331A3 (en) Drug delivery systems
DE60237768D1 (en) MODULATORS PHARMACOLOGICAL AGENTS
WO2005011734A3 (en) Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer
WO2008045228A3 (en) Medical devices having porous regions for controlled therapeutic agent exposure or delivery
WO2004010894A3 (en) Ophthalmologic irrigation solutions and method
WO2006073872A3 (en) Retrograde perfusion of tumor sites
EP2305276A3 (en) Processed lipoaspirate cells for use in therapy
FI3335712T3 (en) METHOD FOR THE SAFE AND EFFECTIVE TREATMENT AND PREVENTION OF SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE
WO2007002572A3 (en) Nattokinase for reducing whole blood viscosity
WO2002000210A3 (en) Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease
Ülkür et al. Effect of hyperbaric oxygen on pedicle flaps with compromised circulation
DE602005025347D1 (en) OLIGORIBONUCLEOTIDES AND METHODS FOR THEIR USE IN THE TREATMENT OF FIBROTIC SUDDEN AND OTHER DISEASES
WO2002043806A3 (en) In vivo delivery methods and compositions
WO2004004664A3 (en) Methods for treating or preventing ischemic injury
WO2005060960A3 (en) Use of histamine to treat bone disease
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
WO2008008317A3 (en) System and method for a low profile vibrating plate
WO2005009217A3 (en) Diagnosis of pre-cancerous conditions using pcdgf agents
Lundblad et al. Effects of L-arginine on cerebral blood flow, microvascular permeability, number of perfused capillaries, and brain water content in the traumatized mouse brain
CA2344910A1 (en) Method for treating renal disease, and pharmaceutical composition for treating renal disease
WO2008060535A3 (en) Use of reversine and analogs for treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP